Information Provided By:
Fly News Breaks for December 27, 2019
Dec 27, 2019 | 07:35 EDT
Raymond James analyst Elliot Wilbur raised his price target for Flexion Therapeutics to $28 from $25 after the FDA approved Zilretta's supplemental New Drug Application to revise the product label language with respect to repeat administration. While unlikely to "significantly alter" the launch trajectory, the news is a positive as it should drive higher utilization rate, as well as favorable marketability around Zilretta, Wilbur tells investors in a research note. The analyst reiterates a Strong Buy rating on Flexion shares.
News For FLXN From the Last 2 Days
There are no results for your query FLXN